# US 2013/0156869 A1 · Pharmaceutical composition for the treatment of alzheimer's disease, method for producing same and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156869 A1
- Document ID: US20130156869A1
- Status: Published application
- Kind: A1
- Application number: 13/639,228
- Filed: 2011-04-07
- Published: 2013-06-20
- Earliest claimed: 2010-04-07
- Assignees: Funddacao Arnaldo Vieira de Carvalho
- Inventors: Marielza Andrade Nunes; Hudson de Sousa Buck
- Web page: https://patentgrep.com/patent/US20130156869A1

## CPC

- A61K 31/191: having two or more hydroxy groups, e.g. gluconic acid
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides the use of lithium compounds in micro-doses for the treatment of Alzheimer's disease. The results show that the administration of lithium in micro-doses provides a known not-toxic alternative to the elderly for slowing or stopping the progress of the disease and the progressive cognitive deterioration.

## Claims

### Claim 1

A pharmaceutical composition for the curative or prophylactic treatment of Alzheimer's disease characterized in that it comprises
a) a pharmaceutically acceptable carrier; and
b) up to 0.28 mg daily of at least one active ingredient selected from the group comprising lithium salts or combinations thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition according to claim 1, comprising lithium compounds in microdoses.

### Claim 3 (depends on 1)

A pharmaceutical composition according to claim 1, characterized in that said lithium salt is lithium gluconate, lithium carbonate or combinations thereof.

### Claim 4

A process for the preparation of a pharmaceutical composition for the curative or prophylactic treatment of Alzheimer's disease, comprising formulating a pharmaceutically acceptable carrier with at least one active ingredient comprising between x and y (concentration) of compounds selected from lithium, or combinations thereof.

### Claim 5

The use of lithium compounds in microdoses in the preparation of medicaments for the curative or prophylactic treatment of Alzheimer's disease.